Investing.com - Financial Markets Worldwide
Open in App

Beiley Biofund Inc (7882)

TPEX
Currency in TWD
25.10
-1.00(-3.83%)
Closed·

7882 Income Statement

Period Ending:
2023
31/12
2024
31/12
2025
31/12
Total Revenues
139.5140.541,227.26
Total Revenues Growth
-+0.74%+773.27%
Cost Of Revenues
---
Gross Profit
139.5140.541,227.26
Gross Profit Growth
-+0.74%+773.27%
Gross Profit Margin %
100%100%100%
Other Operating Expenses, Total
57.5851.6772.32
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
--10.26%+39.97%
---
57.449.8272.32
---
Operating Income
81.9288.871,154.95
Operating Income Growth
-+8.48%+1,199.6%
EBIT Margin %
58.73%63.24%94.11%
Net Interest Expenses
4.0515.1816.78
Net Interest Expenses Growth
-+274.81%+10.56%
Interest Expense, Total
-0.01-0.04-0.01
Interest And Investment Income
4.0615.2116.79
Other Non Operating Expenses, Total
1.51.470.59
EBT, Excl. Unusual Items
87.47105.511,172.32
Gain (Loss) On Sale Of Assets
---
Other Unusual Items, Total
---
EBT, Incl. Unusual Items
88.63111.631,172.68
EBT, Incl. Unusual Items Growth
-+25.96%+950.47%
EBT, Incl. Unusual Items Margin
63.53%79.43%95.55%
Income Tax Expense
0.0115.1247.09
Net Income to Company
88.6296.511,125.59
Minority Interest
---
Net Income
88.6296.511,125.59
Net Income Growth
-+8.91%+1,066.28%
Net Income Margin %
63.52%68.67%91.72%
Preferred Dividend and Other Adjustments
---
Net Income to Common Excl. Extra Items
88.6296.511,125.59
Basic EPS - Continuing Operations
0.950.455.3
Basic EPS - Continuing Operations Growth
--52.05%+1,066.28%
Diluted EPS - Continuing Operations
0.950.455.29
Diluted EPS - Continuing Operations Growth
--52.04%+1,065.98%
Basic Weighted Average Shares Outstanding
93.54212.47212.47
Diluted Weighted Average Shares Outstanding
93.54212.49212.58
Dividend Per Share
-0.141.35
Dividend Per Share Growth
--+833.54%
EBITDA
81.9389.681,156.44
EBITDA Growth
-+9.46%+1,189.57%
EBITDA Margin %
58.73%63.81%94.23%
EBIT
81.9288.871,154.95
* In Millions of TWD (except for per share items)

FAQ

What was Beiley Biofund’s revenue at year end?

At the end of the last reported fiscal year, Beiley Biofund (7882) recorded total revenue of 1,227.26 million TWD.

How much revenue did Beiley Biofund report in the most recent quarter?

In its most recent quarterly earnings report, Beiley Biofund posted revenue of -246.77 million TWD.

What was Beiley Biofund’s net income for the year?

For the full year, Beiley Biofund reported net income of 1,125.59 million TWD.

How much net income did Beiley Biofund post in the last quarter?

In the most recent quarter, Beiley Biofund (7882) posted net income of -284.66 million TWD.

What was Beiley Biofund’s gross profit for the year?

Gross profit for the year was reported at 1,227.26 million TWD.

How much gross profit did Beiley Biofund generate last quarter?

Beiley Biofund recorded gross profit of -246.77 million TWD in its latest quarterly report.

What was Beiley Biofund’s annual operating income?

For the full year, Beiley Biofund (7882) reported operating income of 1,154.95 million TWD.

What was Beiley Biofund’s operating income last quarter?

Quarterly operating income was -260.98 million TWD.

What was Beiley Biofund’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -260.78 million TWD.

What was the quarter-over-quarter change in EBITDA for Beiley Biofund?

EBITDA changed by -123.55% million TWD compared to the last quarter.

What is Beiley Biofund’s most recent net income margin?

Net income margin based on recent financials is 115.36% million TWD.

What is Beiley Biofund’s most recent EBIT margin?

Beiley Biofund reported an EBIT margin of 105.76% million TWD based on current figures.

How did Beiley Biofund’s revenue change compared to the previous quarter?

Revenue changed by -121.42% million TWD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Beiley Biofund?

In the latest quarter, gross profit changed by -121.42% million TWD from the previous quarter.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.